MedLife S.A.

Regulatory Filings • Jul 10, 2025

Premiere in Romania: MedLife introduces the most advanced sequencing technology and prepares a large-scale genetic testing program: "Starting October, whole human genome sequencing will be available on a large scale in Romania"

• MedLife will launch, for the first time, a genetic testing program focused on quality of life and aging. The initial investment amounts to EUR 3 million, but this will gradually increase as the program progresses. With this initiative, MedLife becomes the first Romanian company to invest millions of euros in research within Romania—^a significant amount dedicated to scientific advancement and improving public health.
• Whole genome sequencing (WGS) will thus become possible on a large scale in Romania—the most comprehensive and complex genetic diagnostic test—marking a key milestone in the transition toward personalized medicine.
• This fall, MedLife is preparing to launch an innovative health project focused on advanced genetic screening, which will provide access to individual genetic mapping. The program will begin with over 4,000 participants, and the results will form the basis of an extensive research study.
• Currently, the MedLife Group is a leader in the genetics sector, with over 20 years of experience in the field. Since as early as 2006, when MedLife sent its first group of geneticists to the United States for training, the Romanian company has now become the first in the region capable of conducting research programs focused on improving quality of life, using one of the most advanced technologies in the world.

Bucharest, July 10, 2025: MedLife, the largest private medical services network in Romania, announces the acquisition of the most advanced Illumina sequencing equipment – NovaSeq X Plus – and is preparing to launch a large-scale genetic testing program that will bring personalized medicine closer to the Romanian population. This strategic investment marks a new chapter in the evolution of the Romanian medical system, shifting from reactive medicine to a proactive approach based on science, precise data, and prevention.

Through this initiative, MedLife confirms its position as a technology-driven company and a medical operator that continuously revolutionizes medicine in Romania by introducing advanced equipment and innovative approaches in clinical practice. Today, MedLife widely employs robotic surgery in hospitals, transports biological samples using drones, and utilizes fully automated laboratory lines.

The main strengths behind this new initiative are cutting-edge technology and an elite Romanian medical team consisting of geneticists, biologists, biostatisticians, clinicians, and programmers, led by Dr. Dumitru Jardan, coordinator of MedLife's Molecular Biology Laboratory.

An innovative health project in Romania that will facilitate access to individual genetic mapping

In an initial development phase, with the help of this new technology, the MedLife Group will carry out an innovative testing project aimed at generating relevant data about the genetics of Romania's active population, with an impact on quality of life.

The screening project will facilitate access to individual genetic mapping and represents MedLife's response to the need for personalization—both in the therapeutic approach tailored to patients' specific

characteristics and in lifestyle recommendations aimed at early disease prevention and optimizing health. The program will begin in October.

Alongside MedLife, three other major companies in Romania will have the opportunity to be at the forefront of health innovation. The direct beneficiaries will be the employees of these companies who enroll in the program. They will receive personalized medical recommendations, as well as lifestyle advice that, over time, will translate into greater engagement in their own health.

Thus, MedLife continues its mission and commitment to do good through knowledge, carrying on its series of research studies aimed at dispelling fear of the unknown and providing practical, applied solutions to medical challenges.

"This is an investment in the future of medicine and in our ability to democratize genetic testing in Romania and bring prevention to a new level. Everyone talks about improving quality of life, and now, right here in Romania, we will address this need on a large scale, using arguably the most advanced technology in the world, alongside some of the best specialists Romania has today. We are extremely proud to demonstrate that Romanian medicine can achieve excellence at this level.

We aim to build a model through which personalized medicine becomes truly possible, and genetic testing—as a key element in this ecosystem—becomes accessible, relevant, and integrated into everyday life for as many Romanians as possible. Moreover, through this strategic initiative, we will not only innovate in Romania and the entire region, but we will also genuinely help our patients live better— and why not, longer—lives. Everyone talks about extending life and its quality. Well, this is exactly what we will focus on", said Mihai Marcu, CEO & Chairman of the Board MedLife Group.

Cutting-edge technology for a paradigm shift in prevention

The Illumina NovaSeq X Plus is currently one of the most advanced genetic sequencing systems available worldwide, used by centers of excellence such as the Broad Institute in the USA. This equipment enables rapid analysis of the entire human genome with a high degree of accuracy, thereby supporting an efficient and sustainable research model.

Designed to accelerate discoveries in genomics, the Illumina NovaSeq X Plus stands out with: up to three times greater accuracy compared to previous versions; increased efficiency and a much broader testing range, capable of processing 2.5 times more human genomes than its predecessor, the NovaSeq 6000. Additionally, it can test any panel for genetic predisposition and risk. Last but not least, this new technology has a significantly reduced ecological impact, cutting packaging waste by 90% and plastic consumption by 50%.

"By adopting the NovaSeq X Plus system, we are taking a decisive step toward a new era of personalized medicine in Romania. We now have the capacity to analyze the complete genome with exceptional precision and in record time, providing patients with relevant information for prevention, diagnosis, and medical decisions tailored to their genetic profile. This is a firm commitment to a more predictive, efficient, and science-driven medicine." Said Dr. Dumitru Jardan, coordinator of MedLife's Molecular Biology Laboratory.

A new standard for Romanian medicine

Through this initiative, MedLife paves the way for truly personalized medicine by laying the foundation for a new prevention model in which genetics will play a crucial role—not only in establishing diagnoses and treatments but especially in personalizing diet and lifestyle according to the individual genetic profile, with undeniable benefits for quality of life.

This project will contribute, in the long term, to a medical paradigm shift based on prevention, education, and responsibility—a change that will redefine health standards and behaviors among the Romanian population.

Currently, the MedLife Group is the national leader in the genetics segment, boasting over 20 years of experience in the field, the largest number of sequencers in Romania, several research projects carried out especially during the COVID-19 pandemic, and a highly skilled team of doctors and biologists.

***

About MedLife Group

MedLife a pornit acum aproape trei decenii, s-a dezvoltat sănătos și a devenit cel mai mare furnizor de servicii medicale private din România. Antreprenorii români, care au pus bazele acestei companii, au investit și s-au implicat pentru a aduce schimbare în sistemul de sănătate românesc, au crezut în inovație și au îndrăznit să țintească cât mai sus, pentru a oferi pacienților români calitate, profesionalism, grijă și respect pentru nevoile lor.

Compania operează cea mai extinsă reţea de clinici, una din marile reţele de laboratoare medicale, spitale generale şi specializate şi are cea mai mare bază de clienţi corporate pentru Pachete de Prevenţie în Sănătate din țară. Este, de asemenea, din punct de vedere al vânzărilor, unul dintre cei mai mari jucători de servicii medicale private din Europa Centrală și de Est.

Grupul MedLife are un istoric de succes în ceea ce privește atât creșterea organică, cât și creșterea prin achiziții. Echipa sa puternică și experimentată de management a fost capabilă să creeze și să gestioneze aceste oportunități de creștere, dobândind cunoștințe și experiență valoroase, care să îi permită găsirea celei mai bune căi pentru continuarea cu succes a extinderii.

Fiind o companie românească cu tradiție, MedLife a ales să se listeze la Bursa din România, fiind un model al listărilor pe piața locală de capital. A deschis orizonturi, iar prin guvernanța corporativă pe care o are implementată, a inspirat și alte companii locale spre a porni pe acest drum și a ajuta la dezvoltarea capitalului românesc și a economiei. Acțiunile emise de MedLife SA sunt admise la tranzacționare pe piața reglementată la vedere administrată de Bursa de Valori București, Categoria Premium, având simbolul de tranzacționare ″M″.

În perioada de pandemie, MedLife a reușit să joace un rol esențial în societate și să capete un statut de lider în monitorizarea pandemiei prin implicarea activă în zona de cercetare.

Compania continuă să investească în proiecte cu impact asupra comunității locale, în tehnologie și infrastructură. Creează locuri de muncă și dezvoltă un ecosistem care contribuie la dezvoltarea și menținerea unei Românii sănătoase.